A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
Active inflammatory bowel disease within 28 days prior to first dose
Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
Had wounds or fractures that had not been healed for a long time
Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
Participants with any severe and/or uncontrolled disease
Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
Failure to control serous effusions requiring repeated drainage
Local radiotherapy or 4. Bone marrow irradiation \> 30% for bone metastasis before the first medication
Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
Previous history of severe allergy of unknown origin
According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Clareo Health | A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
